Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05623839 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3305677 in Participants With Obesity Or Overweight
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05623839 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 32 participants.
The verdict
NCT05623839, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.
Interventions
- DRUG Placebo
- DRUG LY3305677
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2023-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05623839
The ClinicalTrials.gov registry entry for NCT05623839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05623839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05623839 about?
NCT05623839 is a clinical study titled "A Study of LY3305677 in Participants With Obesity Or Overweight". The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will ...
What is the current status of trial NCT05623839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-11-16. Estimated completion is 2023-06-27.
What interventions are being tested in trial NCT05623839?
The interventions under investigation include: Placebo (DRUG), LY3305677 (DRUG).
Who is sponsoring clinical trial NCT05623839?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.